Home＞BUSINESS
Eisai’s Midterm Strategy Focusing on Neurology, Oncology “Gradually Producing Results”: CEO Naito(Nov.2.2016)
Eisai CEO Haruo Naito |
Eisai’s strategy focusing on neurology and oncology set in its midterm business plan, dubbed “EWAY 2025” kicked off in April, “is gradually producing results,” stressed CEO Haruo Naito at an earnings briefing on October 31. “Particularly, we see steady progress in our pipeline,” he added ...
(LOG IN FOR FULL STORY)
-
Eisai CEO Sees 4 Global Brands as Drivers through FY2020
Nov.02
- Eisai’s BACE Inhibitor Enters PIII, Enrollment Begins in US Nov.01
-
Forex Moves Drag Down Eisai’s Half-Year Sales despite Bullish Global Brands
Nov.01
- 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai Oct.13
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy Oct.03
-
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
